Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD is on ResearchGate
AMYPAD is on ResearchGate 05 Jun 2018 AMYPAD has now a page in the networking platform ResearchGate. Welcome to our ResearchGate page......
Job vacancy - Doctoral Position
Job vacancy - Doctoral Position 28 May 2018 BBRC invites applications for a full-time graduate student position within the context of the AMYPAD project
...
Interview with Laure Saint-Aubert
Interview with Laure Saint-Aubert 28 May 2018 I joined the AMYPAD consortium in August 2017 as Project Manager of the French site of Toulouse. As such, I am in charge of assisting our Site coordinator Pr Pierre Payoux in management and monitoring of the two trials......
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.